In their meta-analysis, Bradburn et al. established blood IL-6 as a risk factor for cognitive decline in MCI patients, with high IL-6 levels being associated with an increased risk of an AD diagnosis at a follow-up visit within 2–7 years (odds ratio, 1.42) [112]. The gene discussed is IL6; the disease is Alzheimer disease.